1525 GMT - GSK's 2025 outlook is promising, fueled by the sales growth expectations for its specialty medicines, Quilter Cheviot healthcare analyst Sheena Berry says in a note. The British pharma giant's clinical results for its chronic-cough drug candidate and regulatory decisions on a potential comeback of its blood-disorder treatment Blenrep are crucial for the group's future trajectory, she says. Shares are up 6.7% at 14.73 pounds.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 05, 2025 10:25 ET (15:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.